Medications comparable in terms of symptom response and adherence, but weight loss greater with dexamphetamine
FRIDAY, July 17, 2026 (HealthDay News) — For children and adolescents with attention-deficit/hyperactivity disorder (ADHD), comparable, significant symptom improvement is seen with dexamphetamine and methylphenidate, but weight loss is greater with dexamphetamine at three months, according to a study published online July 7 in the Journal of Paediatrics and Child Health.
Alison Poulton, M.D., from The University of Sydney, and colleagues conducted an open-label study involving 100 stimulant-naive children and adolescents with ADHD. Participants were randomly assigned to receive dexamphetamine or methylphenidate and followed for 12 months.
The researchers found that at all time periods, there were significant ADHD symptom improvements on either medication, with no significant difference seen between the groups. Sixty-two of the participants remained on their allocated medication at 12 months, with no significant difference between methylphenidate and dexamphetamine (68 versus 56 percent). Weight loss was seen in association with both medications, with greater weight loss on dexamphetamine at three months (−1.44 versus −0.31 kg).
“Both medications worked equally well for improving ADHD symptoms, and a year later most children were still taking their original stimulant, suggesting a comparable level of satisfaction with either medication,” Poulton said in a statement. “The main difference was that children taking dexamphetamine experienced greater weight loss, which is an important consideration when choosing treatment and monitoring growth.”
One author disclosed ties to the pharmaceutical and publishing industries.
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Dose-Dependent Link Seen for Clomiphene Citrate, Adverse Perinatal Outcomes
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine